Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.
The primary endpoint was triglyceride reduction at 12 and 26 weeks. The trial evaluated 278 patients.
The U.S. expansion will recruit up to 30,000 adults over the age of 18 years from a broad range of racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions.
Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints.
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
AstraZeneca’s Farxiga (dapagliflozin) dramatically prolonged survival in patients with chronic kidney disease in a Phase III clinical trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 28, 2020.
The trials were identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies that evaluated tapinarof cream, 1% in adults with plaque psoriasis.
PRESS RELEASES